Drug Discovery
clinical studies will be more efficient use of the total life science R&D spend ($71.1 billion in 201612) and presumably higher success rates of drugs to treat disease.
DDW
Continued from page 62
Dr Nicole Perfito is a Core Team member for the Reproducibility Project: Cancer Biology and has contributed to other reproducibility projects includ- ing the Prostate Cancer Foundation-Movember Foundation Reproducibility Initiative. Completing her PhD in Biology at the University of Washington, her research focused on reproductive physiology and neuroendocrinology while at Princeton, the Max Planck Institute and the University of California, Berkeley. Currently, Nicole leads a team of staff scientists to deliver outsourced experimental services to leading R&D organisations.
Dr Rachel Tsui has a PhD in Biochemistry from UC San Diego, focusing on both signal transduc- tion and computational biochemistry, and a BA in Chemistry from Boston University. At Science Exchange, Rachel collaborates with procurement and R&D leadership to optimise research out- sourcing. Before Science Exchange, Rachel worked as a sales and marketing consultant in the pharma- ceutical and healthcare space for ZS Associates, with a focus on marketing strategy for pipeline and launched oncology drugs.
Dr Elizabeth Iorns is the Founder & CEO of Science Exchange, the Co-Director of the Reproducibility Initiative and is a part-time partner at Y Combinator. Elizabeth has a PhD in Cancer Biology from the Institute of Cancer Research (UK), and before starting Science Exchange in 2011 was an Assistant Professor at the University of Miami (where she remains an Adjunct Professor). Elizabeth has received a range of honours and recognition, including the Kauffman Foundation Emerging Entrepreneur Award, one of Nature Magazine’s ‘Ten People Who Mattered’ and one of WIRED’s ‘50 Women Who Are Changing The World’. Elizabeth is focused on the development of innovative models to promote the quality and effi- ciency of scientific research.
Drug Discovery World Winter 2017/18
8 Aird, F, Kandela, I, Mantis, C. Reproducibility Project: Cancer Biology. 2017. Replication study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. eLife 6:e21253. 9 Horrigan, SK, Courville, P, Sampsey, D, Zhou, F, Cai, S. Reproducibility Project: Cancer Biology. 2017b. Replication study: Melanoma genome sequencing reveals frequent PREX2 mutations. eLife 6:e21634. 10 BIO, Biomedtracker, Amplion. 2016. Clinical Development Success Rates 2006-2015. 11 Hay, M, Thomas, DW, Craighead, JL, Economides, C, Rosenthal, J. 2014. Clinical development success rates for investigational drugs. Nat Biotech 32: 40-51. doi:10.1038/nbt.2786. 12 IRI, 2016. 2016 Global R&D Funding Forecast. R&D Magazine Winter 2016. 13 Horrigan, S. Reproducibility Project: Cancer Biology. 2017a. Replication study: The CD47- signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. eLife 6:e18173. 14 Kandela, I, Aird, F. Reproducibility Project: Cancer Biology. 2017. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. eLife 6:e17044. 15 Mantis, C, Kandela, I, Aird, F. Reproducibility Project: Cancer Biology. 2017. Replication study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. eLife 6:e17854. 16 Showalter, MR, Hatakeyama, J, Cajka, T, VanderVorst, K, Carraway, KL, Fiehn, O. Reproducibility Project: Cancer Biology. 2017. Replication Study: The common feature of leukemia- associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2- hydroxyglutarate. Elife. 2017 Jun 27;6. pii:e26030. doi: 10.7554/eLife.26030.
63
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
